search
Back to results

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Primary Purpose

Keratoconjunctivitis Sicca

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
1% Tavilermide Ophthalmic Solution
Placebo Ophthalmic Solution
Sponsored by
Mimetogen Pharmaceuticals USA, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Keratoconjunctivitis Sicca focused on measuring Dry Eye

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Be at least 18 years of age Provided written informed consent Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye

Exclusion Criteria:

Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months Have any planned ocular and/or lid surgeries over the study period Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1 Have an uncontrolled systemic disease Be a woman who is pregnant, nursing or planning a pregnancy Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study Have a known allergy and/or sensitivity to the test article or its components Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits

Sites / Locations

  • MIM-727 Investigational Site
  • MIM-727 Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Tavilermide Ophthalmic Solution

Vehicle Ophthalmic Solution

Arm Description

1% Tavilermide Ophthalmic Solution

Placebo Ophthalmic Solution

Outcomes

Primary Outcome Measures

Corneal Fluorescein Staining
Ocular Discomfort

Secondary Outcome Measures

Corneal Fluorescein Staining
Ocular Surface Disease Index
Ocular Dryness

Full Information

First Posted
December 16, 2015
Last Updated
August 13, 2019
Sponsor
Mimetogen Pharmaceuticals USA, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02634853
Brief Title
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
Official Title
A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mimetogen Pharmaceuticals USA, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keratoconjunctivitis Sicca
Keywords
Dry Eye

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
429 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tavilermide Ophthalmic Solution
Arm Type
Active Comparator
Arm Description
1% Tavilermide Ophthalmic Solution
Arm Title
Vehicle Ophthalmic Solution
Arm Type
Placebo Comparator
Arm Description
Placebo Ophthalmic Solution
Intervention Type
Drug
Intervention Name(s)
1% Tavilermide Ophthalmic Solution
Intervention Description
1% Tavilermide BID Dosing
Intervention Type
Drug
Intervention Name(s)
Placebo Ophthalmic Solution
Intervention Description
Vehicle Ophthalmic Solution
Primary Outcome Measure Information:
Title
Corneal Fluorescein Staining
Time Frame
Day 57
Title
Ocular Discomfort
Time Frame
Day 57
Secondary Outcome Measure Information:
Title
Corneal Fluorescein Staining
Time Frame
Day 15
Title
Ocular Surface Disease Index
Time Frame
Day 57
Title
Ocular Dryness
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be at least 18 years of age Provided written informed consent Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months Have any planned ocular and/or lid surgeries over the study period Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1 Have an uncontrolled systemic disease Be a woman who is pregnant, nursing or planning a pregnancy Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study Have a known allergy and/or sensitivity to the test article or its components Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Garth Cumberlidge, PhD
Organizational Affiliation
Mimetogen Pharmaceuticals USA, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
MIM-727 Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
MIM-727 Investigational Site
City
Nashville
State/Province
Tennessee
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

We'll reach out to this number within 24 hrs